126 related articles for article (PubMed ID: 15160964)
21. Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
van den Anker-Lugtenburg PJ; Sizoo W
Am J Hematol; 1990 Feb; 33(2):152. PubMed ID: 2301374
[No Abstract] [Full Text] [Related]
22. [Treatment of essential thrombocythemia--personal experience].
Bieniaszewska M; Balon J; Brozek I; Limon J; Hellmann A
Pol Arch Med Wewn; 2000; 103(3-4):179-85. PubMed ID: 11236245
[TBL] [Abstract][Full Text] [Related]
23. Multiple myeloma following essential thrombocythemia.
Ben Youssef Y; Gmidène A; Bouabid Z; Bouallegui S; Sriha B; Zaier M; Sennana H; Khelif A
Ann Biol Clin (Paris); 2013; 71(4):457-60. PubMed ID: 23906574
[TBL] [Abstract][Full Text] [Related]
24. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
25. Essential thrombocythemia developing into refractory anemia and complicated by acute myeloid leukemia.
Yonekura S; Nagao T; Arimori S
Intern Med; 1992 Oct; 31(10):1224-7. PubMed ID: 1286233
[TBL] [Abstract][Full Text] [Related]
26. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
27. Hydroxyurea as a cause of drug fever.
Braester A; Quitt M
Acta Haematol; 2000; 104(1):50-1. PubMed ID: 11111124
[TBL] [Abstract][Full Text] [Related]
28. Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.
Santoro C; Sperduti I; Latagliata R; Baldacci E; Anaclerico B; Avvisati G; Breccia M; Buccisano F; Cedrone M; Cimino G; De Gregoris C; De Muro M; Di Veroli A; Leonetti Crescenzi S; Montanaro M; Montefusco E; Porrini R; Rago A; Spadea A; Spirito F; Villivà N; Andriani A; Alimena G; Mazzucconi MG
Cancer Med; 2017 Jun; 6(6):1233-1239. PubMed ID: 28544749
[TBL] [Abstract][Full Text] [Related]
29. Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.
Renso R; Aroldi A; Pioltelli P; Gambacorti-Passerini C; Elli EM
Blood Cancer J; 2018 Jun; 8(6):56. PubMed ID: 29891835
[No Abstract] [Full Text] [Related]
30. Renal cancer after busulphan treatment for chronic myeloid leukemia. A case report.
Iurlo A; Foa P; Sala M; Maiolo AT
Tumori; 1993 Aug; 79(4):278-9. PubMed ID: 8249184
[TBL] [Abstract][Full Text] [Related]
31. Plasma cell leukemia: a rare condition.
Jiménez-Zepeda VH; Domínguez VJ
Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
33. Hydroxyurea-induced hemolytic anemia in a patient with essential thrombocythemia.
Jabr FI; Shamseddine A; Taher A
Am J Hematol; 2004 Dec; 77(4):374-6. PubMed ID: 15558807
[TBL] [Abstract][Full Text] [Related]
34. [Acute myeloid leukemia developing in the course of essential thrombocythemia].
Fernández MC; Gardelegui I; Capote FJ; Gil JL; Muñoz JA
Sangre (Barc); 1996 Oct; 41(5):405-6. PubMed ID: 9026932
[No Abstract] [Full Text] [Related]
35. [Essential thrombocythemia: conventional therapy].
Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
[No Abstract] [Full Text] [Related]
36. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Samuelson B; Chai-Adisaksopha C; Garcia D
J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476
[TBL] [Abstract][Full Text] [Related]
37. [Subcutaneous myeloid sarcoma in a patient with essential thrombocythemia that transformed into acute myeloid leukemia].
Kuroda H; Jomen W; Yoshida M; Usami M; Shimoyama S; Yamada M; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Nagashima K; Uemura S; Kanari Y; Kato J
Gan To Kagaku Ryoho; 2015 Feb; 42(2):215-9. PubMed ID: 25743142
[TBL] [Abstract][Full Text] [Related]
38. Coexistence of chronic lymphocytic leukemia and essential thrombocythemia.
Robak T; Urbańska-Ryś H; Góra-Tybor J; Wawrzyniak E; Korycka A; Bartkowiak J; Kordek R; Polliack A
Leuk Lymphoma; 2003 Aug; 44(8):1425-31. PubMed ID: 12952240
[TBL] [Abstract][Full Text] [Related]
39. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia.
Shvidel L; Sigler E; Haran M; Klepfish A; Duek A; Berrebi A; Shtalrid M
Leukemia; 2007 Sep; 21(9):2071-2. PubMed ID: 17611572
[No Abstract] [Full Text] [Related]
40. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
Mesquita Mdo C; Sol EB; Malarme M; Noubouossie D; Demulder AC
Clin Ther; 2009 Nov; 31(11):2559-64. PubMed ID: 20110000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
